设计,合成,抗癌活性,以及基于伊米达佐的新衍生物的in silico计算研究,这些衍生物具有潜在的多目标激酶抑制活性
Nesreen S Ahmed1, Somaia S Abd El-Karim1, Manal M Anwar1
1Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre (NRC), El Bohouth St., Dokki, Cairo 12622, Egypt.
合成了针对结肠癌激酶的新型化合物. 化合物1c和2h显示出强大的抗增殖作用和多酶抑制,2h还诱导了细胞亡和细胞循环停止,表明了新的癌症疗法的潜力.
科学领域:
- 药用化学 医学化学
- 癌症生物学 癌症生物学
- 分子药理学分子药理学
背景情况:
- 结肠癌仍然是一个重大的健康问题,需要开发新的治疗药物.
- 针对参与癌症进展的多个激酶是有效治疗的有希望的策略.
- 伊米达佐利丁衍生物为设计多向激酶抑制剂提供了多功能支架.
研究的目的:
- 设计和合成新型的5-(3,5-dimethoxybenzylidene)-2-thioxoimidazolidin-4-one衍生物.
- 评估这些化合物对结肠癌细胞的抗增殖活性.
- 研究它们作为多酶抑制剂的潜力及其作用机制.
主要方法:
- 新型伊米达佐利丁衍生物 (1a-d和2a-h化合物) 的合成.
- 使用MTT对HT-29结肠癌细胞进行抗增殖试验.
- 在体外激酶抑制对VEGFR-2,c-Met和PIM-1的测试.
- 细胞亡和细胞循环分析 (流细胞计).
- 分子对接和在中的ADMET研究.
主要成果:
- 化合物1c和2h对HT-29细胞表现出显著的抗增殖作用 (IC50值为1.828和2.197微克/毫升).
- 这些衍生物对VEGFR-2,c-Met和PIM-1 (IC50值为0.0810.433μg/mL) 显示出强大的多酶抑制.
- 化合物2h诱导的亡,G0/G1细胞周期停止,以及调节的亡相关蛋白 (caspase-3,caspase-9,Bax/Bcl-2比率).
- 对接和分子动力学模拟证实了与目标激酶的强有力的结合相互作用.
- 在基中ADMET分析预测了有利的药理动力学特性和低毒性.
结论:
- 新的伊米达佐利丁衍生物显示出作为抗结肠癌药物的巨大潜力.
- 化合物1c和2h的多向激酶抑制是它们有效性的关键机制.
- 化合物2h诱导细胞亡和细胞循环停止的能力需要进一步调查.
- 这些化合物具有有利的类似药物的特性,支持它们在药物开发管道中的进步.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
相关概念视频
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
